Dec

    Pharmaceutical Patent Settlements: How the Turducken is Made

    11 AM EST

    "Reverse payment" patent settlement cases have been called a “turducken,” referring to the complexity of litigating a patent case inside an antitrust case. Following the Supreme Court’s Actavis decision, we have seen the turducken peeled back and examined repeatedly. But how does a pharmaceutical patent settlement come to be, and how are companies managing their antitrust risk in the post-Actavis environment? This panel will offer a unique look at these questions by taking the audience through the process of patent litigation, settlement considerations, antitrust review, and, ultimately, FTC review, with the help of experts who are involved every step of the way.

     

    $25
    NON-MEMBERS
    $10
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Moderator:  David Emanuelson, Intel Corporation

    Speakers:

    Ryan Foley, Novartis Corporation
    Paul Fehlner, Axcella Health
    Maren Schmidt, Federal Trade Commission

    FREE:  Antitrust Section Members, Government, Non-profit Employees, Students, and $25.00 Other Non-Members. 

    Explore Section benefits or call 1-800-285-2221 to join.   Or explore more at:  https://www.americanbar.org/groups/antitrust_law/

    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive: Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

    Event Details

    Format

    Teleconference

    Date

    Dec 17, 2018

    2018-12-17T11:00:00-05:00 2018-12-17T12:00:00-05:00 Pharmaceutical Patent Settlements: How the Turducken is Made

    "Reverse payment" patent settlement cases have been called a “turducken,” referring to the complexity of litigating a patent case inside an antitrust case. Following the Supreme Court’s Actavis decision, we have seen the turducken peeled back and examined repeatedly. But how does a pharmaceutical patent settlement come to be, and how are companies managing their antitrust risk in the post-Actavis environment? This panel will offer a unique look at these questions by taking the audience through the process of patent litigation, settlement considerations, antitrust review, and, ultimately, FTC review, with the help of experts who are involved every step of the way.

     

    Speakers

    J Schmidt

    Federal Trade Commission

    Ryan Foley

    Novartis International AG

    Sponsors

    Intellectual Property

    Section of Antitrust Law

    Moderators

    Related Products

    Related On-Demand CLE